Value for Money? An Analysis of Five Product-Driven M&A Deals

By Heather Cartwright & Dan Roberts

Pharma Deals Review: Vol 2017 Issue 12 (Table of Contents)

Published: 29 Dec-2017

DOI: 10.3833/pdr.v2017.i12.2292     ISSN: 1756-7874

Section: Opinion & Analysis

Fulltext:

Abstract

Big pharma has shown little appetite for large-scale M&A in recent years, but has remained willing to pay sizeable sums in order to access highly coveted near-term revenue drivers via bolt-on acquisitions...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

PharmaDeals has now moved to a new platform (https://analyticslink.customerportal.iqvia.com). The current PharmaDeals website will be disabled from October 31, 2026. Please update your bookmarks and, if you have any issues accessing the new platform, please contact your IQVIA account manager.

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details